241 related articles for article (PubMed ID: 31974142)
21. Fenofibrate, HDL, and cardiovascular disease in Type-2 diabetes: The DAIS trial.
Tsunoda F; Asztalos IB; Horvath KV; Steiner G; Schaefer EJ; Asztalos BF
Atherosclerosis; 2016 Apr; 247():35-39. PubMed ID: 26854974
[TBL] [Abstract][Full Text] [Related]
22. Fenofibrate: a review of its use in dyslipidaemia.
McKeage K; Keating GM
Drugs; 2011 Oct; 71(14):1917-46. PubMed ID: 21942979
[TBL] [Abstract][Full Text] [Related]
23. [HDL cholesterol reduction during rosiglitazone and fenofibrate treatment in a type 2 diabetes mellitus patient with dyslipidemia].
Im M; Kim M; Lee JK; Chang YH; Lee DY; Hong SI; Lee YY; Hong YJ
Korean J Lab Med; 2010 Feb; 30(1):17-9. PubMed ID: 20197717
[TBL] [Abstract][Full Text] [Related]
24. Summarizing the FIELD study: lessons from a 'negative' trial.
Tsimihodimos V; Mikhailidis DP; Elisaf M
Expert Opin Pharmacother; 2013 Dec; 14(18):2601-10. PubMed ID: 24206060
[TBL] [Abstract][Full Text] [Related]
25. The influence of fenofibrate on lipid profile, endothelial dysfunction, and inflammatory markers in type 2 diabetes mellitus patients with typical and mixed dyslipidemia.
Ghani RA; Bin Yaakob I; Wahab NA; Zainudin S; Mustafa N; Sukor N; Wan Mohamud WN; Kadir KA; Kamaruddin NA
J Clin Lipidol; 2013; 7(5):446-53. PubMed ID: 24079286
[TBL] [Abstract][Full Text] [Related]
26. Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes.
Mottl AK; Buse JB; Ismail-Beigi F; Sigal RJ; Pedley CF; Papademetriou V; Simmons DL; Katz L; Mychaleckyj JC; Craven TE
Clin J Am Soc Nephrol; 2018 Nov; 13(11):1693-1702. PubMed ID: 30361335
[TBL] [Abstract][Full Text] [Related]
27. [Fibrates therapy: Rational use fenofibrate 2016. Executive summary].
Brea A; Millán J; Ascaso JF; Blasco M; Díaz A; González-Santos P; Hernández-Mijares A; Mantilla T; Pedro-Botet JC; Pintó X;
Clin Investig Arterioscler; 2016; 28(6):295-301. PubMed ID: 27609708
[TBL] [Abstract][Full Text] [Related]
28. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study.
Chew EY; Davis MD; Danis RP; Lovato JF; Perdue LH; Greven C; Genuth S; Goff DC; Leiter LA; Ismail-Beigi F; Ambrosius WT;
Ophthalmology; 2014 Dec; 121(12):2443-51. PubMed ID: 25172198
[TBL] [Abstract][Full Text] [Related]
29. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2012 Nov; 11():140. PubMed ID: 23150952
[TBL] [Abstract][Full Text] [Related]
30. Effects of medical therapies on retinopathy progression in type 2 diabetes.
; ; Chew EY; Ambrosius WT; Davis MD; Danis RP; Gangaputra S; Greven CM; Hubbard L; Esser BA; Lovato JF; Perdue LH; Goff DC; Cushman WC; Ginsberg HN; Elam MB; Genuth S; Gerstein HC; Schubart U; Fine LJ
N Engl J Med; 2010 Jul; 363(3):233-44. PubMed ID: 20587587
[TBL] [Abstract][Full Text] [Related]
31. Fenofibrate and metabolic syndrome.
Kraja AT; Province MA; Straka RJ; Ordovas JM; Borecki IB; Arnett DK
Endocr Metab Immune Disord Drug Targets; 2010 Jun; 10(2):138-48. PubMed ID: 20406163
[TBL] [Abstract][Full Text] [Related]
32. Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.
Brautbar A; Covarrubias D; Belmont J; Lara-Garduno F; Virani SS; Jones PH; Leal SM; Ballantyne CM
Atherosclerosis; 2011 Dec; 219(2):737-42. PubMed ID: 21889769
[TBL] [Abstract][Full Text] [Related]
33. [Clinical study of the month. Accord-lipid and accord-eye: towards a new positioning of fenofibrate in the management of type 2 diabetes].
Scheen AJ; Van Gaal LF
Rev Med Liege; 2010 Sep; 65(9):533-9. PubMed ID: 21086587
[TBL] [Abstract][Full Text] [Related]
34. Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.
Rotroff DM; Pijut SS; Marvel SW; Jack JR; Havener TM; Pujol A; Schluter A; Graf GA; Ginsberg HN; Shah HS; Gao H; Morieri ML; Doria A; Mychaleckyi JC; McLeod HL; Buse JB; Wagner MJ; Motsinger-Reif AA;
Clin Pharmacol Ther; 2018 Apr; 103(4):712-721. PubMed ID: 28736931
[TBL] [Abstract][Full Text] [Related]
35. Fenofibrate effects on arterial endothelial function in adults with type 2 diabetes mellitus: A FIELD substudy.
Harmer JA; Keech AC; Veillard AS; Skilton MR; Marwick TH; Watts GF; Meredith IT; Celermajer DS;
Atherosclerosis; 2015 Sep; 242(1):295-302. PubMed ID: 26233916
[TBL] [Abstract][Full Text] [Related]
36. Different effects of fenofibrate on cardiometabolic risk factors in young women with and without hyperprolactinemia.
Krysiak R; Szkróbka W; Okopień B
Pharmacol Rep; 2019 Feb; 71(1):61-66. PubMed ID: 30469130
[TBL] [Abstract][Full Text] [Related]
37. A genome-wide study of lipid response to fenofibrate in Caucasians: a combined analysis of the GOLDN and ACCORD studies.
Irvin MR; Rotroff DM; Aslibekyan S; Zhi D; Hidalgo B; Motsinger-Reif A; Marvel S; Srinivasasainagendra V; Claas SA; Buse JB; Straka RJ; Ordovas JM; Borecki IB; Guo X; Chen IY; Rotter JI; Wagner MJ; Arnett DK
Pharmacogenet Genomics; 2016 Jul; 26(7):324-33. PubMed ID: 27002377
[TBL] [Abstract][Full Text] [Related]
38. Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins.
Anabtawi A; Moriarty PM; Miles JM
Curr Cardiol Rep; 2017 Jul; 19(7):62. PubMed ID: 28528456
[TBL] [Abstract][Full Text] [Related]
39. [Field, a randomized clinical trial of cardiovascular prevention with fenofibrate in type 2 diabetes].
Radermecker RP; Scheen AJ
Rev Med Liege; 2005 Dec; 60(12):957-61. PubMed ID: 16457397
[TBL] [Abstract][Full Text] [Related]
40. Effects of combination lipid therapy in type 2 diabetes mellitus.
; Ginsberg HN; Elam MB; Lovato LC; Crouse JR; Leiter LA; Linz P; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm RH; Ismail-Beigi F; Bigger JT; Goff DC; Cushman WC; Simons-Morton DG; Byington RP
N Engl J Med; 2010 Apr; 362(17):1563-74. PubMed ID: 20228404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]